NEW YORK, Feb. 07, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical-stage biopharmaceutical company focused on the development of transforming immuno-oncology cancer therapies, today announced that Dr. Lan Huang, co-founder and CEO, will present at two upcoming investor conferences this month:
- BIO CEO & Investor Conference, Feb. 12, 2018, 2 p.m. EST: Dr. Huang will participate in a fireside chat, moderated by Dr. Joseph Pantginis, Managing Director at H.C. Wainwright. The discussion will highlight BeyondSpring’s innovative oncology pipeline, as well as the market for new medicines and evolution of biomedical research among biopharmaceutical companies, particularly in leveraging resources in China.
- RBC Capital Markets 2018 Healthcare Conference, Feb. 21, 2018, at 2:35 p.m. EST: Dr. Huang will provide a corporate overview, highlighting the first-in-class immuno-oncology asset Plinabulin, its registrational clinical programs and opportunity in large markets, including chemotherapy-induced neutropenia (CIN) and non-small cell lung cancer.
A live webcast of the RBC Capital Markets presentation will be available online, which can be accessed through the Investor Relations section of BeyondSpring’s website: http://ir.beyondspringpharma.com. Also, a replay of the webcast will be available on http://ir.beyondspringpharma.com following the event.
BeyondSpring is a global clinical stage biopharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with University of Washington in de novo drug discovery using ubiquitination platform. BeyondSpring’s lead asset, Plinabulin, is in a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer (Study 103) and two Phase 2/3 clinical programs in the prevention of chemotherapy-induced neutropenia (CIN) – (Studies 105 and 106). BeyondSpring has a seasoned management team with many years of experience bringing drugs to market.
Studies on Plinabulin's mechanism of action indicate that Plinabulin activates GEF-H1, a guanine nucleotide exchange factor. GEF-H1 activates downstream transduction pathways leading to the activation of the protein c-Jun. Activated c-Jun enters the nucleus of dendritic cells to up-regulate immune-related genes, which contributes to the up-regulation of a series of genes leading to dendritic cell maturation, T-cell activation and other effects that prevent neutropenia. To reduce CIN, Plinabulin is given as a single IV infusion in each cycle, 30 minutes to 1 hour after completion of the chemotherapy, offering same day dosing, whereas G-CSF is given 24 hours after chemotherapy. In addition, the use of Plinabulin is not associated with bone pain, which is a frequent side effect with G-CSF.
Cautionary Note Regarding Forward-Looking Statements
This press release includes forward-looking statements that are not historical facts. Words such as "will," "expect," "anticipate," "plan," "believe," "design," "may," "future," "estimate," "predict," "objective," "goal," or variations thereof and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, the anticipated amount needed to finance the company's future operations, unexpected results of clinical trials, delays or denial in regulatory approval process, our expectations regarding the potential safety, efficacy or clinical utility of our product candidates, or additional competition in the market. The forward-looking statements made herein speak only as of the date of this release and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.
Steve Silver / Jeffrey Goldberger
KCSA Strategic Communications
email@example.com / firstname.lastname@example.org
Caitlin Kasunich / Amy Singh
KCSA Strategic Communications
212.896.1241 / 212.896.1207
email@example.com / firstname.lastname@example.org